Disparate systemic and renal blocking properties of angiotensin II antagonists during exogenous angiotensin II administration: Implications for treatment

Journal of Human Hypertension

Volumn 18, Issue 12, 2004, Pages 857-863

  Willemsen, J M ^a   Rabelink, T J ^b   Boer, P ^a   Gaillard, C A ^a,c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MEANDER MEDICAL CENTER   (Netherlands)

Author keywords

Angiotensin II; Angiotensin II receptor blocker; Candesartan cilexetil; Hypertension; Losartan; Renin angiotensin system

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL; LOSARTAN; PLACEBO;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ANGIOTENSIN BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; ARTICLE; ATTENUATION; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; FEMALE; GLOMERULUS FILTRATION RATE; HEMODYNAMICS; HUMAN; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY PLASMA FLOW; KIDNEY VASCULAR RESISTANCE; MALE; PATHOGENESIS; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; CHILD; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION; KIDNEY; LOSARTAN; MIDDLE AGED; RENAL CIRCULATION; RENIN; TETRAZOLES;

EID: 10044284156     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001769     Document Type: Article

References (32)

1. Folkow B. The pathophysiology of hypertension. Drugs 1993; 46: 3-7.
2. Navis GJ, de Zeeuw D, de Jong PE. Enalapril and the kidney: renal vasodilation and natriuresis due to the inhibition of angiotensin II formation. J Cardiovasc Pharmacol 1998; 8: S30-S34.
3. Brenner BM et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
4. Parving HH et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
5. Navar LG, Imig JD, Zou L, Wang CT. Intrarenal production of angiotensin II. Semin Nephrol 1997; 17: 412-422.
6. Siragy HM, Howell NL, Ragsdale NV, Carey RM. Renal interstitial fluid angiotensin: modulation by anesthesia, epinephrine, sodium depletion, and renin inhibition. Hypertension 1995; 25 1021-1024.
7. Siragy HM, Carey RM. Protective role of the angiotensin AT2 receptor in a renal wrap hypertension model. Hypertension 1999; 33: 1237-1242.
8. Tsutsumi Y et al. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 1999; 104: 925-935.
9. Andersson CK, Neldain S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Press 1998; 7: 251-252.
10. Conlin PR et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? (see comments). Am J Hypertens 2000; 13: 418-426.
11. Morsing P. Candesartan: a new-generation angiotensin II AT1 receptor blocker: pharmacology, antihypertensive efficacy, renal function, and renoprotection. J Am Soc Nephrol 1999; 10(Suppl 11): 248-254.
12. Shibouta Y et al. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl]-1H- benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H- benzimidazole-7-carboxylate (TCV-116). Pharmacol Exp Ther 1993; 266: 114-120.
13. Heyrowski A. A new method for determination of inulin in plasma and urine. Clin Chim Acta 1956; 1: 470-474.
14. Waugh WH, Beall PT. Simplified measurements of p-aminohippurate and other arylamines in plasma and urine. Kidney Int 1974; 5: 429-436.
15. Boer P et al. Blood and extracellular fluid volume in patients with Barrter's syndrome. Arch Intern Med 1983; 143: 1902-1905.
16. Boer WH et al. Effects of reduced renal perfusion pressure and acute volume expansion on proximal tubule and whole kidney angiotensin II content in the rat. Kidney Int 1997; 51: 44-49.
17. Gradman AH et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995; 25: 1345-1350.
18. Ikeda LS et al. Comparative antihypertensive effects of losartan 50 mg and losartan 50 mg titrated to 100 mg in patients with essential hypertension. Blood Press 1997; 6: 35-43.
19. Timmermans PB et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45: 205-251.
20. Fuchs B et al. Comparative pharmacodynamics and pharmacokinetics of candesartan and losartan in man. J Pharm Pharmacol 2000; 52: 1075-1083.
21. Fridman K. Candesartan cilexetil and renal hemodynamics in hypertensive patients. AJH 2000; 13: 1045-1048.
22. Kawabata M et al. Effects of an angiotensin II receptor antagonist, TCV-116, on renal haemodynamics in essential hypertension. Blood Press Suppl 1994; 5: 117-121.
23. Gandhi SK, Ryder DH, Brown NJ. Losartan blocks aldosterone and renal vascular responses to angiotensin II in humans. Hypertension 1996; 28: 961-966.
24. Schmitt F et al. Acute renal effects of AT1-receptor blockade after exogenous angiotensin II infusion in healthy subjects. J Cardiovasc Pharmacol 1998; 31: 314-321.
25. Sechi LA, Grady Riffin CA, Kalinyak JE, Schambelan M. Distribution of angiotensin II receptor subtypes in rat and human kidney. Am J Physiol 1992; 262: F236-F240.
26. Endo Y et al. Function of angiotensin II type 2 receptor in the postglomerular efferent arteriole. Kidney Int 1997; 63: S205-S207.
27. Mitchell KD, Navar LG. Superficial nephron responses to peritubular capillary infusions of angiotensin I and II. Am J Physiol 1987; 252: F818-F824 (Renal Fluid Electrol Physiol 27 ).
28. Rosivall L, Navcar LG. Effects on renal hemodynamics of intra-arterial infusions of angiotensins I and II. Am J Physiol 1983; 252: F181-F187 (Renal Fluid Electrol Physiol 14).
29. Carey RM, Wang ZQ, Siragy HM. Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension 2000; 35: 155-163.
30. Goldfarb DA et al. Angiotensin II receptor subtypes in the human renal cortex and renal cell carcinoma. J Urol 1994; 151: 208-213.
31. Grone HJ, Simon M, Fuchs E. Autoradiographic characterization of angiotensin receptor subtypes in fetal and adult human kidney. Am J Physiol 1992; 262: 326-331.
32. Ardaillou R. Angiotensin II receptors. J Am Soc Nephrol 1999; 10(Suppl 11): 30-39.